#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Mucous membrane pemphigoid Neurofibroma Pulmonary hypertension Intracranial germ cell tumour Hairy cell leukaemia recurrent Plasma cell myeloma Macular telangiectasia Uveal melanoma Henoch-Schonlein purpura Oesophageal adenocarcinoma Cutaneous T-cell lymphoma stage I Leiomyosarcoma metastatic Essential thrombocythaemia Metastatic malignant melanoma Juvenile psoriatic arthritis More trials…

    Learn about Rare Diseases

    Toxic epidermal necrolysis Metachromatic leukodystrophy – Life with Disease MELAS syndrome – Life with Disease Friedreich’s ataxia Gastrointestinal stromal tumour – Diagnostics Idiopathic pulmonary fibrosis – Diagnostics Nephroblastoma Haemophagocytic lymphohistiocytosis – Diagnostics X-linked lymphoproliferative syndrome Leiomyosarcoma – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Auto4 Magnesium Chloride Hexahydrate Levonorgestrel LY3537031 Pemafibrate Bromhexine Hydrochloride Crofelemer Pyridoxine Amoxicillin Sodium YL201 Ceftazidime Pentahydrate Xenon Povorcitinib Mannitol Dabigatran Etexilate Remdesivir Andexanet Alfa Mebeverine Hydrochloride Odm-212 Gebasaxturev More therapies…

    Learn about Your Condition

    Angiosarcoma non-metastatic Muscle hypertrophy Aicardi-Goutieres syndrome Bladder cancer recurrent Infantile apnoea Weaning failure Pleomorphic liposarcoma Infertility Keratosis follicular Epidermolysis bullosa Microvillous inclusion disease Pituitary tumour benign Abdominal wall pain Aneurysm ruptured Corticobasal degeneration More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Study on the Long-Term Safety of Dazukibart in Patients with Idiopathic Inflammatory Myopathies, Including Dermatomyositis and Polymyositis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Polymyositis
    • Dermatomyositis
    • Idiopathic inflammatory myopathy
    Investigated Drugs:
    • CHLOROQUINE PHOSPHATE
    • Dazukibart
    • Deflazacort
    Bulgaria Hungary Italy Poland Spain Sweden

  • Study on Eltrombopag for Treating Low and Intermediate Risk Myelodysplastic Syndromes in Patients with Thrombocytopenia

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Eltrombopag
    Italy

  • Study of 99mTc-MIP-1404 SPECT/CT imaging compared to standard imaging methods for detecting lymph node metastases in patients with prostate cancer

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • 18F-Psma-1007
    • TROFOLASTAT
    • Piflufolastat (18F)
    Finland

  • Study on the Safety of Intradermal mRNA COVID-19 Vaccine Bretovameran for Patients with Fibrodysplasia Ossificans Progressiva

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Fibrodysplasia ossificans progressiva
    The Netherlands

  • Study on Using Dapagliflozin, Semaglutide, and Finerenone to Prevent Heart and Kidney Complications in Patients with Type 2 Diabetes

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Dapagliflozin
    • Finerenone
    • Semaglutide
    Denmark Spain

  • Study on Rituximab for Adults with Relapsing Steroid-Sensitive Nephrotic Syndrome

    Recruiting

    3 1 1 1 1
    Investigated Drugs:
    • Rituximab
    Poland
Previous Page
1 … 246 247 248 249 250 … 1,649
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!